Acalabrutinib
Showing 1 - 25 of 137
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Nemtabrutinib
- +2 more
- (no location specified)
Nov 22, 2023
Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- Obinutuzumab
- (no location specified)
Jul 10, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma (MCL)
- Acalabrutinib
- +2 more
-
Duarte, California
- +11 more
Jul 17, 2023
T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)
Not yet recruiting
- T-cell Lymphoma
- CLL/SLL
- Tazemetostat
- Acalabrutinib and Tazemetostat
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 11, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib (Arm A)
- Acalabrutinib (Arm B)
-
Bethesda, MarylandResearch Site
Jan 3, 2023
Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)
Active, not recruiting
- Post-transplant Lymphoproliferative Disorder
- Rituximab
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023
Retention Rate of Acalabrutinib in a Non-interventional Setting
Recruiting
- Chronic Lymphocytic Leukaemia (CLL)
-
Zittau, GermanyResearch Site
Jan 12, 2023
Acalabrutinib in Chronic Lymphocytic Leukaemia in United Kingdom
Recruiting
- Chronic Lymphocytic Leukemia, CLL
- Acalabrutinib
-
Aylesbury, United Kingdom
- +7 more
Jan 12, 2023
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Homburg (R-miniCHOP + Acalabrutinib, R-miniCHOP)
Not yet recruiting
- Large B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- R-miniCHOP + Acalabrutinib
- R-miniCHOP
-
Homburg, Saarland, GermanySaarland University Medical Center
Apr 19, 2023
Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Oct 31, 2022
Bioequivalence Trial in Glendale, Brooklyn, Salt Lake City (Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib
Completed
- Bioequivalence
- Treatment A: Acalabrutinib tablet
- Treatment B: Acalabrutinib capsule
-
Glendale, California
- +2 more
Jul 7, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- Venetoclax
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- +8 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +4 more
-
Scottsdale, Arizona
- +2 more
Jan 5, 2023
Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in United States (Venetoclax, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Venetoclax
- +2 more
-
Stamford, Connecticut
- +4 more
Dec 2, 2022
Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
- Acalabrutinib
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Acalabrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 2, 2022
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)
Active, not recruiting
- Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
- Acalabrutinib capsule
-
Ahmedabad, India
- +12 more
Feb 2, 2023